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Smostly consisting of large HDL(Figure 1). Small HDL was not correlated with EL,
total cholesterol, low density lipoprotein cholesterol (LDL), triglyceride (TG), age.
Large HDL was positively correlated with EL (r¼0.2, p¼0.01), negatively correlated
with age, LDL, TG (r¼0.02, p¼0.007, r¼0.22, p¼0.025, r¼0.42, p<0.001) respec-
tively. If subjects divided into 2 groups as HDL< 40 mg/dL and HDL> 40 mg/dL. EL
levels are 25,79ng/mL and 30,77ng/mL respectively (p¼0.004) (Figure 2).
Conclusion: There were no differences between small HDL concentrations in the
HDL low and high groups. Low HDL concentrations may be functionally effective as
high HDL concentrations. EL concentrations were positively correlated with HDL
levels but EL primarily affects large HDL. Our results in healthy population may serve
as a reference for clinical studies on HDL subfractions.HDL Subfractions According to the HDL Levels
HDL
Concentrations
mg/dL
Small
HDL(HDL3)
Large
HDL(HDL2)
Small/Large
HDL Ratio
HDL <39 19,2+11,0 8,2+10,3 2,2
HDL 40-59 26,4+9,8 21,0+9,6 1,2
HDL >60 24,0+12,4 44,9+20,2 0,6
p¼0.074 for small HDL between HDL<39 and HDL > 60 groups p<0.0001 for large HDL
Table 1
Odds ratio
95% Conﬁdence
interval p value
Hypertension 2.54 1.63-3.95 <0.001
Coronary artery disease 1.51 1.02-2.26 0.039
Peripheral artery disease 2.63 1.19-5.84 0.017
Diabetic retinopathy 1.8 1.20-2.70 0.004
Physical activity 1.69 1.11-2.57 0.013
Age (years)
<40 0.50 0.15-1.65 0.260
40-50 1.13 0.59-2.16 0.707
51-60 1.70 1.01-2.85 0.043
61-70 1.10 0.64-1.90 0.712
Predictors of statin therapy at multivariate logistic regression analysisOP-091
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Introduction: Lipid-lowering therapy (LLT) is a key factor in the prevention of
cardiovascular mortality and morbidity in diabetic patients. Current guidelines have
expanded the population of patients with diabetes for whom aggressive low-density
lipoprotein cholesterol (LDL-C) lowering therapy should be considered. This study
evaluated the management of dyslipidemia in patients with type 2 diabetes in real life.
between HDL<39 and HDL > 60 groupsC42 JACC VMethods: Secondary care physicians in a tertiary center recruited 707 patients. The
prevalence of statin use along with the achievement of cholesterol targets, predictors
for receiving statin, and possible reasons for lack of therapy were investigated.
Results: The mean age of the patients was 5811.04, and 40% were male. Cardio-
vascular disease (CVD) was present in 32% (n¼225) of the patients. There were 499
patients (71%) who had hypertension (HT), 19% (n¼134) had nephropathy, and 23%
(n¼162) had diabetic retinopathy. Only 33% of the patients were on statin therapy,
and this was signiﬁcantly higher in those with cardiovascular disease (47% versus
27%; p<0.001). Most of the patients had LDL-C levels of > 100 mg/dl (77%), with
only 5% having LDL-C levels of < 70 mg/dl. Among patients with CVD, only 7%
achieved the target LDL-C levels of < 70 mg/dl. At multivariate analysis the presence
of CVD, HT, retinopathy, doing regular physical exercise and being at ﬁfth decade of
life were predictors for statin usage (Table 1). Among the patients who were not on
statin therapy, 288 (61%) had never been prescribed LLT previously, and 183
patients (39%) had used statins in the past but had stopped using it. The most
frequent reason for discontinuation of the statin therapy was a physician's advice to
stop the medication. The patients taking statins had similar LDL-C levels as those
who had never been prescribed statins and those who had discontinued their use of
statins on the advice of a physician (123.041.4 vs. 125.133.2, p¼0.333;
123.041.4 vs. 129.033.1 mg/dl; p¼0.116, respectively).
Conclusion: Themajority of diabetic patients are undertreatedwith statins andminority
of them achieve LDL-C target levels. Our ﬁndings suggest that there is a large dis-
crepency between evidence-based recommendations and physicians’ treatment attitudes.OP-092
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Objective: Slow coronary ﬂow (SCF) is a microvascular disorder characterized by
delayed opaciﬁcation of coronary vessels with normal coronary angiogram. It may be
due to endothelial dysfunction and diffuse atherosclerosis. Lipoprotein (a) [Lp(a)] is
related to cardiovascular events. Although various cardiovascular biomarkers have
been studied in patients with SCF, plasma Lp (a) levels have not been studied
previously. We investigated the plasma Lp (a) and ﬁbrinogen levels and the rela-
tionship between plasma Lp (a) and coronary ﬂow rate in patients with SCF.
Methods: The study group consisted of 50 patients with SCF and an age and gender
matched 30 controls who had normal coronary arteries and normal coronary ﬂow.
Coronary ﬂow rates of all patients and control subjects were documented by
Thrombolysis in Myocardial Infarction (TIMI) frame count. We measured plasma Lp
(a), ﬁbrinogen and routine biochemical parameters at the same time in patients with
SCF and control subjects in this cross-sectional observational study.
Results: There were no statistically signiﬁcant differences between the two groups with
respect to body mass index, systolic and diastolic blood pressures, heart rate and the risk
factors for coronary artery disease such as hyperlipidemia, cigarette smoking, family
history and obesity (All p>0.05). The use of aspirin was signiﬁcantly higher in the SCF
group than control group (50% vs 17%, p¼0.004) but there were no signiﬁcant differ-
ences between the two groups with respect to the use of other medications (All p>0.05).
Fasting glucose was signiﬁcantly higher in SCF than controls (p¼0.01). Inversely, high
density lipoprotein (HDL) cholesterol was signiﬁcantly lower in SCF (p¼0.03). There
were no signiﬁcant differences between the two groups with respect to plasma Lp (a) (21
mg/dL vs 14mg/dL, p¼0.11) and ﬁbrinogen (278mg/dL vs 291mg/dL, p¼0.48) levels.
Themean TIMI frame count was not correlatedwith plasma Lp(a) (r¼0.13, p¼0.25) and
ﬁbrinogen (r¼-0.14, p¼0.28) levels. Similarly, plasma Lp (a) levels were not corralated
with ﬁbrinogen (r¼0.31, p¼0.053) in SCF group.
Conclusion: Our results suggest that Lp (a) appears not to be associated with SCF.ol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/ORALS
